Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in portugal

S. Vaz-Pereira, I.P. Marques, J. Matias, F. Mira, L. Ribeiro, R. Flores

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Purpose: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. Methods: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected. Results: Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p
Original languageEnglish
Pages (from-to)756-761
Number of pages6
JournalEuropean Journal Of Ophthalmology
Issue number6
Publication statusPublished - 2017


  • Anti-VEGF
  • Retinal vein occlusion
  • Visual prognosis
  • bevacizumab
  • ranibizumab
  • vasculotropin antibody
  • adult
  • Article
  • best corrected visual acuity
  • central macular thickness
  • human
  • major clinical study
  • observational study
  • Portugal
  • priority journal
  • retina vein occlusion
  • retrospective study
  • visual acuity


Dive into the research topics of 'Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in portugal'. Together they form a unique fingerprint.

Cite this